You are here: Industry Insights > PD-1

News List

Libtayo® improves overall survival in advanced cervical cancer patients europeanpharmaceuticalreview
March 16, 2021
A Phase III trial evaluating Libtayo® (cemiplimab) monotherapy in advanced cervical cancer has been stopped early due to a positive result on overall survival.
Immutep Secures Second Patent Grant for Eftilagimod Alpha, A Pd-1 Pathway Inhibitor Combination americanpharmaceuticalreview
March 16, 2021
Immutep has announced the grant of patent number 10,940,181 entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent & Trade Mark Office (USPTO).
NMPA Accepts Application for Clinical Trial of Bifunctional Fusion Protein contractpharma
March 10, 2021
JS201, developed by Junshi Biosciences, can simultaneously target PD-1 and TGF-β.
CMAB Biopharma Congratulates Partner Junshi Biosciences on NMPA Acceptance of Application for a Clinical Trial of its PD-1/TGF-β Bifunctional Fusion Protein prnasia
March 08, 2021
Recently, CMAB Biopharma (Suzhou) Inc's partner Shanghai Junshi Biosciences Co., Ltd., announced that a clinical trial application for its PD-1/TGF-β bifunctional fusion protein JS201 injection (JS201) has been accepted by National Medical Products ...
BeiGene announces collaboration with Novartis to develop and commercialize anti-PD-1 antibody Tislelizumab pharmaceutical-business-review
January 14, 2021
BeiGene announced a collaboration and license agreement with Novartis Pharma AG to develop, manufacture and commercialize BeiGene’s anti-PD-1 antibody tislelizumab in the United States, Canada, Mexico, member countries of the European Union ...
China has highest PD-1/PD-L1 combination immuno-oncology therapies clinical trials growth: GlobalData expresspharma
December 01, 2020
Between 2017 and 2019, the number of clinical trials initiated for PD-1/PD-L1 targeted combination therapies increased substantially, which continued in 2020, albeit with a significantly slower rate possibly due to the global COVID-19 pandemic.
Junshi, Merck Collaborate on Head, Neck Cancer Treatment in China americanpharmaceuticalreview
June 11, 2020
Junshi Biosciences and Merck announced their collaboration on a clinical trial program designed to investigate the efficacy and safety of anti-PD-1 mAb toripalimab (TUOYI®) in combination with Cetuximab (Erbitux®) ...
Phase III Lung Cancer Trial Stopped Early Due to Significant Survival Improvement americanpharmaceuticalreview
April 29, 2020
Regeneron and Sanofi announced the primary endpoint of overall survival (OS) was met in a Phase 3 trial comparing the PD-1 inhibitor Libtayo® (cemiplimab).
BioLineRx Announces Notice of Allowance from USPTO for Motixafortide, Anti-PD-1 Combination americanpharmaceuticalreview
March 05, 2020
BioLineRx announced a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application claiming the use of motixafortide (BL-8040).
Researchers determine how a specific protein regulates tumor growth worldpharmanews
January 03, 2020
Immune checkpoints are surface proteins that cancer cells use to evade immune response. These surface proteins are critical for cancer cell growth and drugs targeting these proteins have ...

Previous page 1 2 3 4 Next page